OncoMatch/Clinical Trials/NCT05637216
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Is NCT05637216 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Losartan 25 milligram capsule for radiation induced fibrosis.
Treatment: Losartan 25 milligram capsule — This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Excluded: ATM mutation
Excluded: RAD21 mutation
Excluded: TGFB1 c-509t single-nucleotide polymorphism
Disease stage
Required: Stage 0, I, II, III, IV, TIS, TX
clinical or pathologic stage 0-IV invasive breast cancer to include ductal carcinoma in situ (Tis), primary tumor cannot be assessed (TX) and all other primary tumor stage categories (T1-T4)
Prior therapy
Must have received: surgery
Has been treated with breast conserving surgery or mastectomy with reconstruction
Cannot have received: radiation therapy
Exception: prior breast radiation therapy
history of prior breast radiation therapy
Lab requirements
Kidney function
creatine ≤ 1.5 x uln, egfr ≥ 60
Liver function
ast ≤ 2.5 x uln, alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vail Health Shaw Cancer Center · Edwards, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify